Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr367 Inhibitors

Olr367 inhibitors represent a specialized category of chemical compounds that are designed to interact with the Olr367 receptor, a specific olfactory receptor belonging to the G-protein coupled receptor (GPCR) superfamily. GPCRs are integral membrane proteins that play a critical role in various physiological processes by transducing extracellular signals into intracellular responses. The Olr367 receptor is one of the many olfactory receptors found in the nasal epithelium, where it is primarily involved in the detection of odor molecules. These receptors are part of a larger family of olfactory receptors that contribute to the complex process of olfaction. Olr367 inhibitors are molecules that can bind to the Olr367 receptor with high specificity, effectively blocking its ability to respond to certain odorants. This inhibition process is typically achieved through competitive binding, where the inhibitor mimics the structure of the natural ligand, preventing the receptor from undergoing the conformational changes necessary for signal transduction.

The study of Olr367 inhibitors provides valuable insights into the molecular mechanisms underlying olfactory perception. By examining how these inhibitors interact with the Olr367 receptor, researchers can gain a deeper understanding of the receptor's structure-activity relationships (SAR). This includes identifying the key amino acid residues involved in ligand binding and receptor activation, as well as elucidating the conformational dynamics of the receptor during the binding process. Additionally, Olr367 inhibitors serve as important tools for probing the functional role of the Olr367 receptor within the broader context of olfactory signaling networks. Through the selective inhibition of this receptor, it is possible to dissect its contribution to olfactory coding, receptor-ligand specificity, and the overall architecture of odorant signal processing. The information gleaned from these studies can further enrich our understanding of GPCR function and the molecular basis of sensory perception, highlighting the intricate interplay between receptor structure and function.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Sunitinib Malate

341031-54-7sc-220177
sc-220177A
sc-220177B
10 mg
100 mg
3 g
$197.00
$520.00
$1093.00
4
(1)

Inhibits multiple receptor tyrosine kinases, potentially disrupting angiogenesis and tumor cell proliferation.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor, potentially halts cell cycle progression in cancer cells.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Inhibits VEGFR, PDGFR, and KIT, potentially disrupting angiogenesis and tumor growth.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK1/2 inhibitor, potentially modulates cytokine signaling involved in myeloproliferative disorders.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

BCL-2 inhibitor, potentially induces apoptosis in cancer cells.

Ribociclib

1211441-98-3sc-507367
10 mg
$450.00
(0)

CDK4/6 inhibitor, potentially arrests cell cycle in hormone receptor-positive breast cancer.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$209.00
$413.00
9
(1)

BCR-ABL inhibitor, potentially effective against chronic myeloid leukemia.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$117.00
$423.00
11
(1)

BRAF inhibitor, potentially effective against melanoma with BRAF mutations.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

BTK inhibitor, potentially affects signaling in B-cell malignancies.